A SINGLE-ARM PHASE 2 STUDY OF DARATUMUMAB IN PREVIOUSLY TREATED STK11/LKB1 MUTATED NON-SMALL CELL LUNG CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Stk11/lkb1 Mutated Non-small Cell Lung Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) Must have a laboratory-confirmed diagnosis of a type of lung cancer called NSCLC that has either spread to other parts of the body or cannot be removed by surgery
    2. 2) Must have an identified STK11/LKB1 mutation
    3. 3) Must have either progressed after trying a PD-(L)1 inhibitor, platinum doublet chemotherapy, and standard targeted therapy for metastatic disease, or you cannot receive or have decided not to receive any other treatment options

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Untreated brain metastases
    2. 2) Leptomeningeal disease
    3. 3) Require supplemental oxygen



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.